Top Companies in the Genome Editing Market

In the rapidly evolving landscape of biotechnology, genome editing stands out as one of the most revolutionary fields, promising groundbreaking advancements in medicine, agriculture, and beyond. As we explore the top companies leading this charge, it becomes evident that each plays a pivotal role in shaping the future of genetic research and applications.

CRISPR Therapeutics

CRISPR Therapeutics pioneers the development of transformative gene-based medicines for serious diseases using CRISPR-Cas9 technology. Their clinical programs and strategic partnerships underscore their leadership in advancing genome editing therapies to benefit patients worldwide.

Company Name CRISPR Therapeutics
Headquarters Zug, Switzerland
Pipeline The following list is of the genome editing pipeline:

  • Exagamglogene Autotemcel (exa-cel): β-thalassemia (Approved in some countries)
  • Exagamglogene Autotemcel (exa-cel): Sickle cell disease (Approved in some countries)
  • CTX211: Type 1 diabetes mellitus (Clinical Trial)
  • CTX320: Lp(a) for cardiovascular disease (Clinical Trial)
  • CTX310: ANGPTL3 for cardiovascular disease (Clinical Trial)
  • CTX131: Anti-CD70 allogeneic Car T (Clinical Trial)
  • CTX112: Anti-CD19 allogeneic CAR T (Clinical Trial)

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. specializes in CRISPR-Cas genome editing technologies, offering tools and services that enable precise genetic modifications across various applications. Their dedication to advancing CRISPR technology positions them as a frontrunner in the biotech industry.

Company Name Caribou Biosciences Inc.
Headquarters California, U.S.
Pipeline In April 2024, Caribou Biosciences, Inc. is a prominent clinical-stage CRISPR genome-editing biopharmaceutical company. The company announced that the FDA had approved its Investigational New Drug (IND) application for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), to treat extrarenal lupus (ERL) and lupus nephritis (LN). It is anticipated that by the end of 2024, a multicenter, open-label GALLOP clinical study including CB-010 in patients with LN and ERL would begin phase 1.

Download a sample of this report @

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. emerges as a stalwart in the genome editing market, leveraging its extensive expertise in life sciences and biotechnology. The company offers a comprehensive suite of tools and technologies, including CRISPR-Cas9 systems, which have become synonymous with precision and efficiency in gene editing. Their commitment to innovation and quality has solidified their position as a leader in the industry.


Lonza, a global leader in biotechnology and pharmaceutical manufacturing, has made significant strides in genome editing through strategic partnerships and cutting-edge research initiatives. Known for their scalable manufacturing solutions and cell therapy technologies, Lonza continues to drive advancements in therapeutic genome editing applications, catering to a wide array of biomedical needs.

Bluebird Bio, Inc.

Bluebird Bio, Inc. focuses on developing potentially transformative gene therapies for severe genetic diseases and cancer. With a robust pipeline of innovative treatments based on gene editing and gene addition technologies, Bluebird Bio aims to deliver sustainable value to patients and stakeholders alike, pushing the boundaries of what is possible in genomic medicine.

OriGene Technologies, Inc.

OriGene Technologies, Inc. excels in providing high-quality research tools for genome-wide studies, including CRISPR libraries and custom cloning services. Their dedication to delivering reliable genomic products has made them a preferred partner for academic and clinical researchers worldwide, contributing significantly to advancements in understanding genetic mechanisms.

New England Biolabs

New England Biolabs has established itself as a pioneer in recombinant and native enzyme research, pivotal for genome editing applications. Their portfolio includes cutting-edge tools like NEBNext® Ultra™ II FS DNA Library Prep Kit for Illumina®, empowering researchers with precise and reliable solutions for genetic analysis and manipulation.

Genscript Biotech Corp

Genscript Biotech Corp is renowned for its expertise in gene synthesis and custom molecular biology services, essential for advancing genome editing techniques. By offering innovative solutions such as CRISPR/Cas9 genome editing services and plasmid DNA preparation, Genscript continues to drive scientific progress in the biotech industry.

Transposagen Biopharmaceuticals, Inc.

Transposagen Biopharmaceuticals, Inc. specializes in genetic modification technologies using the piggyBac™ transposon system, uniquely positioned for applications in gene therapy and biomedical research. Their focus on precision and scalability makes them a key player in developing next-generation therapies through genome editing.

Danaher Corporation

Danaher Corporation’s Life Sciences segment, including businesses like Integrated DNA Technologies (IDT), offers cutting-edge genomic tools and reagents critical for precise genome editing. With a commitment to advancing scientific discovery and improving healthcare outcomes, Danaher remains at the forefront of genomic innovation.

Horizon Discovery Ltd. (Revvity, Inc.)

Horizon Discovery Ltd., operating as Revvity, Inc., provides comprehensive gene editing services and tools tailored to accelerate the development of personalized medicines. Their proprietary Edit-R™ CRISPR-Cas9 technology enables precise genetic modifications, empowering researchers to unravel complex biological questions.

Takara Bio Inc.

Takara Bio Inc. is a key player in the genome editing market, known for its innovative technologies such as CRISPR-Cas9 and SMART™ (Switching Mechanism At 5′ end of RNA Template) technologies. Their solutions are instrumental in advancing basic research, therapeutic development, and agricultural biotechnology.


AstraZeneca combines cutting-edge science with a deep understanding of disease mechanisms to pioneer new treatments that harness the potential of genome editing. Their research collaborations and investments in innovative technologies underscore their commitment to addressing unmet medical needs and improving patient outcomes globally.

Cellectis S.A.

Cellectis S.A. pioneers the development of allogeneic CAR T-cell therapies and uses its TALEN® gene-editing technology to create off-the-shelf CAR T-cells for cancer patients. Their innovative approach to genome editing holds promise for revolutionizing cancer treatment through precision medicine.

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. focuses on developing curative genome editing treatments using CRISPR-Cas9 technology. Their innovative pipeline targets genetic diseases with high unmet medical needs, illustrating their commitment to transforming patient care through precision medicine.

Precision BioSciences

Precision BioSciences utilizes its ARCUS® genome editing platform to develop next-generation therapies with improved specificity and efficiency. Their therapeutic pipeline spans oncology, genetic disorders, and infectious diseases, demonstrating their broad application of genome editing technology.

Editas Medicine

Editas Medicine harnesses the power of CRISPR technology to develop potentially transformative genome editing therapies for a range of genetic diseases. Their innovative approach and strong clinical pipeline position them as a key player in the biotech landscape.

Sangamo Therapeutics

Sangamo Therapeutics pioneers genomic medicine by developing and commercializing therapies based on its zinc finger nuclease (ZFN) genome editing technology. Their focus on genetic cures for monogenic diseases highlights their dedication to advancing genome editing solutions.


Recombinetics applies its gene-editing expertise to agricultural biotechnology, aiming to enhance animal health, welfare, and productivity through precise genetic modifications. Their innovative solutions address global challenges in food sustainability and animal welfare.

Cibus Inc.

Cibus Inc. employs its proprietary Rapid Trait Development System (RTDS™) to develop non-transgenic crop varieties with improved traits through precision gene editing. Their sustainable agricultural solutions highlight the potential of genome editing in meeting future food security needs.

Merck KGaA

Merck KGaA pioneers genome editing technologies through its Life Science division, providing researchers with advanced tools and reagents for precise genetic manipulation. Their commitment to innovation supports scientific breakthroughs across diverse research fields.

To own our research study instantly, Click here @

Read more about Genome Editing Market:

You can place an order or ask any questions, please feel free to contact us at

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us:

By Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.